GlobalData on MSN5d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Pharmabiz4d
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...
Bristol Myers reports no new safety signals observed in five-year Sotyktu data
Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu ...
Bristol Myers Squibb Names New GC as Legal Chief Retires
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Bristol Myers announces new five-year results from POETYK PSO trial
Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...